231
Participants
Start Date
January 3, 2024
Primary Completion Date
September 30, 2024
Study Completion Date
September 30, 2024
Collagenase Clostridium Histolyticum (CCH)
Biologic: Intrafascial injection
Placebo
Intrafascial injection
Endo Site 36, Malvern
Endo Clinical Site 2, Pasadena
Endo Site 12, Suffolk
Endo Site 32, Newport News
Endo Site 23, Stonecrest
Endo Site 7, Lawrenceville
Endo Site 37, Coconut Creek
Endo Site 14, Sweetwater
Endo Clinical Site 3, Pinellas Park
Endo Site 19, Grand Rapids
Endo Site 27, Missoula
Endo Site 31, North Chicago
Endo Site 28, O'Fallon
Endo Site 33, Overland Park
Endo Site 35, Shreveport
Endo Site 25, Moore
Endo Site 17, Dallas
Endo Site 26, Dallas
Endo Site 18, Dallas
Endo Clinical Site 4, Bedford
Endo Site 24, Burleson
Endo Site 30, Fort Worth
Endo Site 15, Houston
Endo Site 34, San Antonio
Endo Site 22, San Antonio
Endo Site 9, McAllen
Endo Clinical Site 1, Georgetown
Endo Clinical Site 5, Salt Lake City
Endo Site 8, Tucson
Endo Site 16, Los Angeles
Endo Site 40, Los Angeles
Endo Site 10, Tarzana
Endo Site 6, Encinitas
Endo Site 13, Corona
Endo Site 11, Fresno
Endo Site 21, San Francisco
Endo Site 20, Castro Valley
Endo Site 39, Portland
Endo Site 38, Westwood
Lead Sponsor
Endo Pharmaceuticals
INDUSTRY